supplementary table 2.docx (22.44 kB)
Supplementary table 2.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies
dataset
posted on 2021-10-23, 12:03 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti|
Supplementary Table 2. Exposure to talazoparib (safety population). |
